MIV Therapeutics Inc
MIV Therapeutics Inc. (MIVT) is an advanced stage, research and development company, that is engaged in the development of biocompatible coatings for stents and other medical devices and advanced drug delivery systems. MIVT is focused in providing healing solutions for cardiovascular disease and other medical conditions. The companies hydroxyapatite (ÃƒÆ’Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬Ãƒâ€¦Ã¢â‚¬Å“HApÃƒÆ’Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬Ãƒâ€šÃ‚Â) based product the VESTAsync coronary drug eluting stent system is in animal studies and human clinical trials. Through its collaborative research agreement with The University of British Columbia MIVT has developed coating technologies that utilize HAp for application on drug delivery systems and medical devices. In addition the company sells the GenX bare-metal coronary stent in Europe. The company is headquartered at Vancouver in British Columbia, Canada.